Pathology News
admin

About admin@pathologynews.com

This author has not yet filled in any details.
So far admin@pathologynews.com has created 1088 blog entries.

January 2024

Diagnexia Applauds UK Government’s Approval of Digital Pathology for Enhanced Cancer Screening

2024-01-09T15:33:33+00:00

Digital pathology will enable quicker and more accurate diagnosis by allowing digital review of tissue samples, facilitating remote reporting, and assisting clinicians in obtaining second opinions. The technology involves whole slide imaging, where high-resolution images of entire glass slides can be viewed and stored digitally. The decision to adopt this approach comes after successful trials demonstrating that digital microscopy is as effective as traditional methods. The rollout across the NHS is expected, with NHS England providing guidance on best practices. The UK National Screening Committee, an independent advisory body, plays a crucial role in guiding these screening initiatives. Digital pathology brings several benefits to both care providers and patients alike:

Diagnexia Applauds UK Government’s Approval of Digital Pathology for Enhanced Cancer Screening2024-01-09T15:33:33+00:00

Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types

2024-01-08T15:04:17+00:00

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, today announced the release of a groundbreaking product developed from Paige’s Pathology Foundation Model, Virchow. Built using one of the largest libraries of digitized images, utilizing unique computational resources provided by Microsoft Research, Paige has developed the first application that can detect cancer across more than 17 different tissue types including skin, lung, and the gastrointestinal tract, along with multiple rare tumor types and metastatic deposits.

Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types2024-01-08T15:04:17+00:00

Bicêtre AP-HP Hospital Integrates An AI Solution From Owkin To Improve The Prediction Of Breast Cancer Relapses

2024-01-07T11:18:06+00:00

Owkin, a Franco-American biotech company, announces a new collaboration with AP-HP, putting artificial intelligence at the service of oncology diagnosis. The Bicêtre AP-HP hospital, a pilot in digital pathology, is now positioning itself as a pioneer by using  “RlapsRisk® BC”, [1] an innovative AI solution designed to help doctors assess patients' risk of relapse suffering from breast cancer. This initiative fully supports the ten-year national strategy to combat cancer, by offering healthcare professionals the cutting-edge tools necessary to improve patient care. With this partnership, Owkin strengthens its commitment to public hospitals in France.

Bicêtre AP-HP Hospital Integrates An AI Solution From Owkin To Improve The Prediction Of Breast Cancer Relapses2024-01-07T11:18:06+00:00

Owkin Enters Into Collaboration Agreement With MSD To Develop AI-based Diagnostics For Cancer

2024-01-06T08:43:40+00:00

Owkin, a French-American biotechnology company that applies artificial intelligence (AI) to drug discovery, development, and diagnostics, has announced that it has entered into a collaboration agreement with MSD, the trade name of Merck & Co Inc., Rahway NJ USA to develop and commercialize AI-powered digital pathology diagnostics for the EU market. Clinical trials have shown that the [...]

Owkin Enters Into Collaboration Agreement With MSD To Develop AI-based Diagnostics For Cancer2024-01-06T08:43:40+00:00

Inking Cell Blocks Enhances Scanning for Complete Digital Images

2026-09-16T12:56:59+00:00

When pathologists examine tissues to diagnose a disease, some samples come from body fluids, such as bronchial washes, rather than from solid tissues. To analyze these liquid cytology samples, pathologists concentrate the cells and embed them in a paraffin block, called a cell block. However, the transparent matrix and sparse cells in cell blocks can make them challenging for digital slide scanners to fully capture in focus.

Inking Cell Blocks Enhances Scanning for Complete Digital Images2026-09-16T12:56:59+00:00

Aiforia Signs A Licensing Agreement With The Mayo Clinic For An AI Model That Improves Prediction Of Colorectal Cancer Recurrence

2024-01-02T14:47:57+00:00

Aiforia has entered into an exclusive licensing agreement with the Mayo Clinic in the United States to globally commercialize an AI model that improves prediction of colorectal cancer recurrence. The AI model was developed in collaboration with the Mayo Clinic. The AI model identifies important histological features of colorectal cancer and provides a recurrence prediction estimate useful for colorectal cancer treatment decisions.  

Aiforia Signs A Licensing Agreement With The Mayo Clinic For An AI Model That Improves Prediction Of Colorectal Cancer Recurrence2024-01-02T14:47:57+00:00

December 2023

Cristina González Gonzalo discusses her journey with the clinical validation of Aiosyn Mitosis Breast

2023-12-20T12:42:51+00:00

Cristina González Gonzalo, Clinical Program Manager at Aiosyn, shares her experiences from the clinical validation of Aiosyn Mitosis Breast. Joining the team in May 2022, she played a crucial role in validating Aiosyn’s mitosis detection AI algorithm. In this interview, she provides insights into ensuring the study’s results are representative, discusses the challenges faced, and outlines her approach to coordinating collaboration with Radboud University Medical Center.

Cristina González Gonzalo discusses her journey with the clinical validation of Aiosyn Mitosis Breast2023-12-20T12:42:51+00:00

Owkin And Cerba Path Collaborate To Transform Breast And Colorectal Cancer Diagnosis Through Integration Of Artificial Intelligence-powered Tests Into Standard Clinical Practice

2023-12-20T09:50:04+00:00

Owkin, a techbio company using artificial intelligence to accelerate precision medicine by discovering and developing new drugs and diagnostics and Cerba Path, the Cerba HealthCare’s network of pathologists, today announced a new partnership. The two companies will work together to integrate Owkin’s cutting-edge AI-driven diagnostics into Cerba Path’s routine digital workflows and further validate AI-based tools for precision medicine.

Owkin And Cerba Path Collaborate To Transform Breast And Colorectal Cancer Diagnosis Through Integration Of Artificial Intelligence-powered Tests Into Standard Clinical Practice2023-12-20T09:50:04+00:00

A Pathologist Helps Avoid A Balls Up

2023-12-18T09:51:27+00:00

Every year, The Pathologist Magazine publishes 'The Power List' of who they see as the most influential international laboratory medicine professionals. I have always feigned a lack of interest in this list, while secretly reading it every year and wishing I might one year make the grade! This year, a friend and, in my opinion, a much more worthy potential recipient of this kind of accolade, Professor Ali Khurram, recommended I apply. 2023 was titled 'The Storybook Edition,' where the magazine asked applicants to come up with a heart-warming, educational, or light-hearted narrative to portray laboratory medicine from a different perspective. After initially writing a conventional article about my career, I had a last-minute change of tack when I remembered the following story from my early consultant experience.

A Pathologist Helps Avoid A Balls Up2023-12-18T09:51:27+00:00
Legal

Bioincyte Ltd is registered in the United Kingdom
under company number 13037659

Get in touch

© Copyright 2025, Bioincyte Ltd

Fields marked with an asterisk (*) are required.
By submitting you agree to our T&C and Privacy Policy

Go to Top